AAAAAA

   
Results: 1-10 |
Results: 10
An extended point-area deconvolution approach for assessing drug input rates
Authors: Yeh, KC Holder, DJ Winchell, GA Wenning, LA Prueksaritanont, T
Citation: Kc. Yeh et al., An extended point-area deconvolution approach for assessing drug input rates, PHARM RES, 18(10), 2001, pp. 1426-1434
Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects
Authors: Prueksaritanont, T Vega, JM Zhao, J Gagliano, K Kuznetsova, O Musser, B Amin, RD Liu, L Roadcap, BA Dilzer, S Lasseter, KC Rogers, JD
Citation: T. Prueksaritanont et al., Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects, J CLIN PHAR, 41(5), 2001, pp. 573-581
beta-oxidation of simvastatin in mouse liver preparations
Authors: Prueksaritanont, T Ma, B Fang, XJ Subramanian, R Yu, J Lin, JH
Citation: T. Prueksaritanont et al., beta-oxidation of simvastatin in mouse liver preparations, DRUG META D, 29(10), 2001, pp. 1251-1255
Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: linking in vitro with in vivo information - Reply
Authors: Prueksaritanont, T Lin, JH Baillie, TA
Citation: T. Prueksaritanont et al., Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: linking in vitro with in vivo information - Reply, BR J CL PH, 49(1), 2000, pp. 89-90
Simvastatin does not affect CYP3A activity, quantified by the erythromycinbreath test and oral midazolam pharmacokinetics, in healthy male subjects
Authors: Prueksaritanont, T Vega, JM Rogers, JD Gagliano, K Greenberg, HE Gillen, L Brucker, MJ McLoughlin, D Wong, PH Waldman, SA
Citation: T. Prueksaritanont et al., Simvastatin does not affect CYP3A activity, quantified by the erythromycinbreath test and oral midazolam pharmacokinetics, in healthy male subjects, J CLIN PHAR, 40(11), 2000, pp. 1274-1279
Drug interactions with calcium channel blockers: Possible involvement of metabolite-intermediate complexation with CYP3A
Authors: Ma, B Prueksaritanont, T Lin, JH
Citation: B. Ma et al., Drug interactions with calcium channel blockers: Possible involvement of metabolite-intermediate complexation with CYP3A, DRUG META D, 28(2), 2000, pp. 125-130
Interspecies comparison and role of human cytochrome P450 and flavin-containing monooxygenase in hepatic metabolism of IL-775,606, a potent 5-HT1D receptor agonist
Authors: Prueksaritanont, T Lu, P Gorham, L Sternfeld, F Vyas, KP
Citation: T. Prueksaritanont et al., Interspecies comparison and role of human cytochrome P450 and flavin-containing monooxygenase in hepatic metabolism of IL-775,606, a potent 5-HT1D receptor agonist, XENOBIOTICA, 30(1), 2000, pp. 47-59
Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations
Authors: Prueksaritanont, T Ma, B Tang, CY Meng, Y Assang, C Lu, P Reider, PJ Lin, JH Baillie, TA
Citation: T. Prueksaritanont et al., Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations, BR J CL PH, 47(3), 1999, pp. 291-298
Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity
Authors: McCrea, J Prueksaritanont, T Gertz, BJ Carides, A Gillen, L Antonello, S Brucker, MJ Miller-Stein, C Osborne, B Waldman, S
Citation: J. Mccrea et al., Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity, J CLIN PHAR, 39(12), 1999, pp. 1212-1220
In vitro and in vivo studies on the metabolism of tirofiban
Authors: Vickers, S Theoharides, AD Arison, B Balani, SK Cui, D Duncan, CA Ellis, JD Gorham, LM Polsky, SL Prueksaritanont, T Ramjit, HG Slaughter, DE Vyas, KP
Citation: S. Vickers et al., In vitro and in vivo studies on the metabolism of tirofiban, DRUG META D, 27(11), 1999, pp. 1360-1366
Risultati: 1-10 |